FDA Clearance Tracker · P150025
PD-L1 IHC 28-8 pharmDx
Last checked: Nov 20, 2026Latest source record: Oct 9, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Oct 9, 2015
Approved
Time to decision
92 days
Received Jul 9, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150025
- Device name
- PD-L1 IHC 28-8 pharmDx
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Jul 9, 2015
- Decided
- Oct 9, 2015
- Decision
- Approved
- Supplements
- 18 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:1) PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTO-CHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48; 2) PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY; AND3) PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC 28-8 PHARMDX IN NON-SQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- We could not check whether this was the first decision under its product code.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.